Latest news with #AtaiLifeSciences
Bloomberg
5 days ago
- Business
- Bloomberg
Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley
Atai Life Sciences NV agreed to buy full control of smaller UK rival Beckley Psytech Ltd. and raised $30 million in fresh equity, as it seeks to cement its position as one of the leading makers of psychedelic drugs for mental health conditions. The German company, which acquired about a 36% stake in Beckley last year, will purchase the remaining shares in an all-stock deal, it said in a statement Monday. The deal values Oxford-based Beckley at about $390 million, according to the statement.
Yahoo
21-05-2025
- Business
- Yahoo
Phase 2a data for BPL-003 ‘encouraging' for Atai Life Sciences, says Jefferies
Jefferies analyst Andrew Tsai notes that Beckley Psytech shared positive Phase 2a data on BPL-003 in combination with SSRI antidepressants for treatment-resistant depression that the firm calls 'encouraging.' The drug's profile seems to be consistent across multiple studies, incrementally de-risking the key Phase 2b TRD study in mid-2025, the analyst tells investors. Although the BPL-003 program is controlled by Beckley Psytech, Atai Life Sciences (ATAI) currently holds about a 34% stake in Beckley that can be increased to 45%-plus for about $60M, adds the analyst, who has a Buy rating and $5 price target on Atai shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on ATAI: Disclaimer & DisclosureReport an Issue Home Depot backs outlook as U.S. sales ticked up: Morning Buzz Atai Life Sciences announces data from Part 2 of Phase 2a study of BPL-003 ATAI Life Sciences: Positioned for Leadership in Scalable Psychedelic Psychiatry with Strong Financial Foundation and Promising Clinical Milestones ATAI Life Sciences: Strong Buy Rating Backed by Promising Trials and Robust Financial Health ATAI Life Sciences: Buy Rating Backed by Promising Pipeline and Strong Cash Position Amid Upcoming Catalysts
Yahoo
04-04-2025
- Business
- Yahoo
Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds?
We recently published a list of . In this article, we are going to take a look at where Atai Life Sciences (NASDAQ:ATAI) stands against other best German stocks to buy according to hedge funds. Germany's economy is facing continued weakness. According to a report published by Roland Berger, the 0.1% contraction in 2023 and the 0.2% in 2o24 will only be countered by a 0.4% projected growth in 2025. While manufacturing orders are recovering modestly since June last year, business sentiments are still low and the industrial production for November was down 3,1% year-over-year. Unemployment also reached 2.81 million in December 2024, which was a 170,000 increase as compared to the same period last year. This pushed the unemployment rate to 6%. Inflation is now expected to average 2% in 2025, which is still down from the 2.2% figure from 2024. Earlier on March 6, Chris Verrone, Strategas, joined CNBC's 'Fast Money' to express his bullish outlook on the European market. He highlighted a shift in global cyclicality eastward and observed that the European industrials are achieving new highs. Verrone emphasized that the European banks have shown strength over the past 18 months but despite such trends, investors are still not heavily leaning towards European equities. He cited the German ETF under the name of EWG to support his stance, as EWG broke a 20-year high which indicated its departure from prolonged secular stagnation particularly within banks and industrials. However, he did note that energy and basic resources are not showing the same momentum. The conversation also covered the fact that investors have been overweight in US large-cap tech stocks over the past 12 to 13 years. Verrone relayed that observed extreme bearishness towards the European market as of December 2024, when he visited the region. He particularly noted that peripheral European markets, which include countries like Italy and Spain, have been leading. Whereas Germany has lagged. While Verrone mentioned that he heard Christine Lagarde, President of the European Central Bank, expressed pessimism about the European economy herself during the world economic forum in Davos, he still maintains his bullish outlook. He thinks that the European economic data is improving and global cyclicality has not been extinguished. We used the Finviz stock screener to compile an initial list of top German stocks. We then selected 12 German stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey's database which tracks the moves of over 900 elite money managers. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. Number of Hedge Fund Holders: 14 Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that develops innovative therapeutics for mental health disorders like depression, anxiety, and addiction. Its pipeline features compounds that range from psilocybin and MDMA derivatives to novel neuromodulators and formulations of established substances. The company is focused on its BPL-003 program which is developed by Beckley Psytech, as a key driver for its growth in the treatment-resistant depression (TRD) market. BPL-003 is an intranasal formulation of mebufotenin benzoate that is designed for rapid and durable antidepressant effects. The Phase 2b clinical trial for its evaluation has completed enrollment of 196 patients across 38 sites in 6 countries, with topline results expected in mid-2025. This trial is assessing the efficacy and safety of single doses of BPL-003 against a sub-perceptual dose, with efficacy measured using the Montgomery-Asberg Depression Rating Scale (MADRS). The Phase 2a study of BPL-003 demonstrated promising results and showed a 55% remission rate on Day 29 and a 45% remission rate on Day 85, with patients dischargeable in under two hours post-dose. Atai Life Sciences' (NASDAQ:ATAI) financial position is strengthened by a recent equity offering that extends its operational runway into 2027. Overall, ATAI ranks 6th on our list of best German stocks to buy according to hedge funds. While we acknowledge the growth potential of ATAI, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATAI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
